BR0307041A - Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes - Google Patents

Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes

Info

Publication number
BR0307041A
BR0307041A BR0307041-7A BR0307041A BR0307041A BR 0307041 A BR0307041 A BR 0307041A BR 0307041 A BR0307041 A BR 0307041A BR 0307041 A BR0307041 A BR 0307041A
Authority
BR
Brazil
Prior art keywords
inflammatory
bodies
treatment
autoimmune diseases
synthetic
Prior art date
Application number
BR0307041-7A
Other languages
English (en)
Inventor
Anthony E Bolton
Arkady Mandel
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of BR0307041A publication Critical patent/BR0307041A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G19/00—Compounds of tin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G15/00—Compounds of gallium, indium or thallium
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/24—Electrically-conducting paints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)

Abstract

"CORPOS DE FOSFOLIPìDIO E USO DOS MESMOS NO TRATAMENTO DE DOENçAS INFLAMATóRIAS E AUTOIMUNES". A presente invenção se refere a composições sintéticas e semi-sintéticas tendo atividade biológica e aos usos das mesmas no tratamento e/ou profilaxia de vários distúrbios em pacientes mamífero. Mais particularmente, ela se refere ao preparo e uso de corpos sintéticos e semi-sintéticos os quais, após introdução no corpo de um paciente, produzem efeitos anti-inflamatórios, órgão-protetores e regulatórios imunes benéficos. A invenção também se refere a tratamentos e composições para alívio de doenças inflamatórias e autoimunes e seus sintomas.
BR0307041-7A 2002-01-21 2003-01-21 Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes BR0307041A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CA002368656A CA2368656A1 (en) 2002-01-21 2002-01-21 Receptor-ligand pairing for anti-inflammatory response
US5138102A 2002-01-22 2002-01-22
US35142702P 2002-01-28 2002-01-28
US36462002P 2002-03-18 2002-03-18
US37210602P 2002-04-15 2002-04-15
US40085702P 2002-08-02 2002-08-02
PCT/CA2003/000064 WO2003061666A1 (en) 2002-01-21 2003-01-21 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases

Publications (1)

Publication Number Publication Date
BR0307041A true BR0307041A (pt) 2004-10-26

Family

ID=27617925

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0307018-2A BR0307018A (pt) 2002-01-21 2003-01-21 Corpos e veìculos farmaceuticamente aceitáveis de fosfato-glicerol
BR0307041-7A BR0307041A (pt) 2002-01-21 2003-01-21 Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0307018-2A BR0307018A (pt) 2002-01-21 2003-01-21 Corpos e veìculos farmaceuticamente aceitáveis de fosfato-glicerol

Country Status (14)

Country Link
US (3) US20030175334A1 (pt)
EP (2) EP1467741A1 (pt)
JP (2) JP2005515243A (pt)
KR (1) KR20040089118A (pt)
CN (1) CN1620301A (pt)
AR (2) AR047005A1 (pt)
BR (2) BR0307018A (pt)
CA (5) CA2368656A1 (pt)
EA (1) EA007426B1 (pt)
MA (1) MA27168A1 (pt)
MX (1) MXPA04007042A (pt)
PE (1) PE20030973A1 (pt)
TW (2) TW200302281A (pt)
WO (3) WO2003061620A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058698A1 (en) * 2002-01-21 2005-03-17 Nolan Yvonne Mairead Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease
WO2004082688A1 (en) * 2003-03-20 2004-09-30 Vasogen Ireland Limited Phosphatidylglycerol (pg) receptor agonists and antagonists
AU2004257375A1 (en) * 2003-07-21 2005-01-27 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
PE20060661A1 (es) * 2004-09-15 2006-09-16 Vasogen Ireland Ltd Composicion que comprende liposomas para el tratamiento de escleorosis multiple
WO2006107107A1 (ja) * 2005-04-01 2006-10-12 Fumitaka Ohsuzu リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法
CA2622475A1 (en) * 2005-09-26 2007-04-05 Vasogen Ireland Limited Treatment of inflammation and vascular abnormalities of the eye
EP1933813A4 (en) * 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER
WO2007131329A1 (en) * 2006-05-12 2007-11-22 Vasogen Ireland Limited Treatment of ubiquitin-proteasome system dysfunction related disorders
BR112012003834A2 (pt) * 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
PL2861214T3 (pl) * 2012-06-14 2021-02-08 Universität Bern Liposomy przystosowane do leczenia zakażeń bakteryjnych
JP6417648B2 (ja) * 2013-07-30 2018-11-07 株式会社豊田中央研究所 エタノールアミンリン酸の利用
US20170112861A1 (en) * 2014-04-04 2017-04-27 Osaka University Drug delivery enhancer comprising substance for activating lysophospholipid receptors
JP6103143B1 (ja) * 2015-05-18 2017-03-29 不二製油株式会社 ＩＬ−１β産生抑制作用を有する食品添加用組成物
PL3316856T3 (pl) 2015-06-30 2021-10-25 Sequessome Technology Holdings Limited Zmieszane formulacje
EP3589278B1 (en) 2017-03-02 2026-01-14 Combioxin SA Liposomes for inhibiting biofilm formation
CN115531399A (zh) * 2022-09-15 2022-12-30 首都医科大学 溶血磷脂酰胆碱在治疗阿尔茨海默病中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518718A1 (fr) * 1981-12-23 1983-06-24 Djelalian Madeleine Procede pour capter et exploiter au maximum le rayonnement solaire global, dispositifs pour la mise en oeuvre de ce procede et capteurs solaires en resultant
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5229376A (en) * 1986-09-25 1993-07-20 The United States Of America As Represented By The Secretary Of The Army Encapsulated plant-derived phosphatidylinositol (PI) compositions for the prevention of mitogenically induced cell proliferation
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
US4863739A (en) * 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
FR2617170B1 (fr) * 1987-06-25 1989-12-22 Inst Nat Sante Rech Med Nouveaux derives peptidiques et leur application notamment en therapeutique
AU633078B2 (en) * 1989-04-04 1993-01-21 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
DE69018460T2 (de) * 1989-04-18 1995-11-09 Vestar Inc Markierung mit liposomen von ischämischen geweben.
FR2658418B1 (fr) * 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
US5188951A (en) * 1990-04-17 1993-02-23 The Liposome Company, Inc. Enzymatic synthesis of soluble phosphatides from phospholipids
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
IT1249063B (it) * 1991-05-28 1995-02-11 Fidia Spa Impiego di derivati fosfolipidici per la preparazione di composizioni farmaceutiche aventi attivita' immunosoppressiva
EP0673384A4 (en) * 1992-12-10 1996-10-09 Univ Minnesota POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES.
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
ES2072223B1 (es) * 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
AU1751795A (en) * 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
JPH08183740A (ja) * 1994-12-28 1996-07-16 Nippon Steel Corp 細胞接着阻害剤及び該阻害剤を含む抗炎症剤
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
CN1200036A (zh) * 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
US5736157A (en) * 1995-10-11 1998-04-07 Williams; Kevin Jon Method of regulating cholesterol related genes, enzymes and other compounds, and pharmaceutical compositions
US6491922B1 (en) * 1996-02-09 2002-12-10 Cornell Research Foundation, Inc. Methods and compounds for treating autoimmune and vascular disease
EP0914094A4 (en) * 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
JPH11308562A (ja) * 1998-04-20 1999-11-05 Minolta Co Ltd デジタルカメラシステム
US6251932B1 (en) * 1998-09-25 2001-06-26 Asta Medica Ag Immunophilin ligands
US6828306B2 (en) * 2000-07-31 2004-12-07 Ottawa Heart Institute Research Corporation Charged lipid compositions and methods for their use

Also Published As

Publication number Publication date
WO2003061666A1 (en) 2003-07-31
US20040013718A1 (en) 2004-01-22
JP2005515242A (ja) 2005-05-26
KR20040089118A (ko) 2004-10-20
AR038203A1 (es) 2005-01-05
EA200400888A1 (ru) 2005-04-28
WO2003061620A2 (en) 2003-07-31
BR0307018A (pt) 2005-02-09
AR047005A1 (es) 2006-01-04
MA27168A1 (fr) 2005-01-03
WO2003061620A3 (en) 2003-10-16
EP1467741A1 (en) 2004-10-20
WO2003061667A1 (en) 2003-07-31
CN1620301A (zh) 2005-05-25
CA2473395A1 (en) 2003-07-31
EP1467740A1 (en) 2004-10-20
MXPA04007042A (es) 2005-06-20
EA007426B1 (ru) 2006-10-27
US20030175334A1 (en) 2003-09-18
CA2416791A1 (en) 2003-07-21
CA2368656A1 (en) 2003-07-21
JP2005515243A (ja) 2005-05-26
TW200302281A (en) 2003-08-01
TW200302735A (en) 2003-08-16
US20080160074A1 (en) 2008-07-03
CA2473490A1 (en) 2003-07-31
PE20030973A1 (es) 2003-12-09
TWI283181B (en) 2007-07-01
CA2471740A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
BRPI0411295A (pt) compostos e seu uso na terapia
DOP2008000001A (es) Oxazolidinonas substituidas y su uso
DK1071439T3 (da) Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
Kirk et al. Tocopherol administration to patients with Dupuytren's contracture; effect on plasma tocopherol levels and degree of contracture.
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
Spies et al. Prednisone and Prednisolone as Therapeutic Agents: Progress Report on Their Integration into General Medical Practice
BRPI0418963A (pt) composição para redução de gordura localizada, uso de compostos tensoativos farmceuticamente aceitáveis e métodos para redução de gordura localizada
US7438937B2 (en) Topical burn composition containing Mentha haplocalyx and one or both of Aloe vera and recombinant human epidermal growth factor
BR0210910A (pt) Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes
CN111631991A (zh) 一种私密护理洗液
WO2001089538A3 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
SE0401943D0 (sv) New use
LEVENSON et al. THE TREATMENT OF BURNS OF THE EXTREMITIES: WITH CLOSE FITTING PLASTER OF PARIS CASTS
Al-Ali et al. The Burn Wounds Treatment; A Clinical Comparison Study between Moist Exposed Burn Ointment and Silver Sulphadiazine: Burn Wounds Treatment & Moist Exposed Burn Ointment and Silver Sulphadiazine
CN116585404B (zh) 一种治疗成人单纯性皮肤瘙痒症的外用中药组合物及制备方法
Mcdaniel et al. Psychoendocrine functions in relation to level of spinal cord transection
HU207446B (en) Method for producing medicinal preparation of local use
RU2549498C1 (ru) Лекарственное средство для лечения экссудативно-гиперемической и эрозивно-язвенной форм красного плоского лишая слизистой оболочки полости рта
Haber PODOPHYLIN TREATMENT OF GENITAL WARTS
KR100564153B1 (ko) 아토피성 피부염을 개선시키는 조성물
Gade et al. Randomized clinical trial for the assessment of the effect of Katibasti in symptom Katishoola (lumbar pain)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/683, 9/127; A61P 37/00

Ipc: A61K 31/683 (2011.01), A61K 9/127 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.